Canada’s Bio-Solutions Likes U.S. HME Market

MONTREAL — On Wednesday, Canada’s Bio-Solutions Corp.
announced that it plans to enter the U.S. HME market.

“Recently, after having multiple organically built ‘mom and pop’
operations approach us, our board and management have decided this
would be a beneficial direction to grow and expand our company,”
Dr. Gilles Chaumillon, CEO and president, said in a release.

It’s no wonder. The company estimates the market at $26 billion
a year and said it is growing at 6 percent annually.

Market entry shouldn’t be hard, the company’s June 15 release
stated: “There are literally hundreds of small American made
companies in this arena. A lot of them were built by Baby Boomers
themselves looking for an exit strategy as private equity has dried
up for what the market deems as smaller players.”

While many of those smaller companies are thinking about the
downside of competitive bidding, Bio-Solutions sees it as an
opportunity, Chaumillon said.

“We at Bio see a vast opportunity with Round 2 of Medicare DMEPOS competitive
bidding being initiated before 2013. Recent changes will
dictate that DME companies must transition away from the
traditional fee schedule and enter competitive bidding … As a
company, our goal is to align ourselves with those in the
competitive bidding process, as well as those working with various
Medicare reimbursement programs. The product lines are endless,”
Chaumillon stated.

Incorporated in Nevada, the company, which makes an organic
insecticide and dietary supplements for livestock, said it has
hired U.S. consultants to get its new move going.

Said Chaumillon, “Nothing would make me happier than to grow our
business, at the same time trying to put Americans back to work. Is
that not what it’s all about?”